# Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition.

## Abstract
In the prepn. of a cytoprotective pharmaceutical compsn., a lipoxygenase inhibitor I is used. The pref. I is of formula Ia . X O, S or NR in the 1 or 3 posn. R H, 1 6C alkyl, CN or Ph Y O, Se, S, SO, SO2 or NR thr broken line represents an opt. double bond between the 1 and 2 or 2 and 3 posn. R1, R2, R3 and R4 H, 1 6C alkyl, 2 6C alkenyl, CH2 nM or any 2 may be joined to form a 5 6C ring opt. unsatd. n 0 6 M OR5, halogen, CF3, SR5, opt. substd. Ph, COOR6, COR14, tetrazole, NHCOR7, NR8R9, NHSO2R10, COCH2OH, SOR11, CONR8R9, SO2NR8R9, SO2R3, NO2, OCOR14, OCONR8R9, OCOOR, CN or NR15R16 R5 H, lower alkoxy lower alkyl, lower acyloxy lower alkyl, 1 6C alkyl benzyl or opt. substd. Ph the Ph substit. here and in R1 R4 is 1 3C alkyl, halogen, CN, CF3, COOR6, CH2COOR6, CH2 mR8R9 1 3C alkoxy, OH, halo 1 6C alkyl, CH2 pCOOR6, CN, formyl, perfluoroalkyl or CH2R12 m 0 2 p 0 6 R6 H, Ph or 1 6C alkyl R12 1 5C alkyl, Ph or dimethylamino R14 H, CH2 qCOOR6 1 6C alkyl, CF3 or Ph opt. substd. as in R5 q 0 4 R7 1 6C alkyl, benzyl or Ph R8, R9 H, Ph opt. substd. as in R5, 1 4C alkyl, 1 4C alkylamino alkyl, or may be joined through the N to form a 5 8 membered heterocycloalkyl R10 OH, 1 6C alkyl, 1 6C alkoxy, Ph or CF3 R11 1 6C alkyl, Ph opt. substd. as in R5, CH2 5COOR6, CN, formyl or perfluoro 1 4C alkyl s 1 6 R13 OH, H, 1 6C alkyl, Ph opt. substd. as in R5 CH2 5COOR6, CN or perfluoro 1 4C alkyl R15, R16 are such that NHR15R16 is an essential amino acid T H, halogen of CF3.

## Claims
CLAIMS 1. Use of a lipoxygenase inhibitor in a process for the production of a cytoprotective pharmaceutical composition which contains as cytopro tective active ingredient at least one lipoxygenase inhibitor. 2. Use according to patent claim 1, characterized in that the used . lipoxygenase inhibitor is a compound of formula IEMI74.1 wherein X is in the 1 or 3 position and is 0, S or NR R is H, C1 C6 branched or linear alkyl, CN or phenyl Y is 0, Se, S, SO, S02 or NR and the broken line represents an optional double bond between the 1 and 2 or 2 and 3 position R1, R2, R3 and R4 are each independently selected from 1 hydrogen 2 alkyl having 1 6 carbon atoms, 3 alkenyl having 2 6 carbon atoms, 4 CH2 nM wherein n is 0 6 and M is a OR5, b halogen, c CF3, d SR5 wherein R5 is H lower alkoxyl loweralkyl lower acyloxy loweralkyl C1 C6 alkyl benzyl phenyl or substituted phenyl wherein the substituents are C1 C3 alkyl, halogen, CN,CF3, COOR6, CH2COOR6, CH2 nNR8R9 wherein n is O to 2,C1 C3 alkoxy, OH, halo C1 C6 alkyl CH2 mCOOR6, wherein m is 0 to 6 and R6 is H, phenyl or C1 C6 alkyl CN, formyl perfluoroalkyl or CH2 R12, wherein R12 is C1 C5 alkyl, phenyl or dimethylamino e phenyl or substituted phenyl as defined above forR5 f COOR6 EMI76.1 wherein R14 isH, C H2 n COOR6 wherein n is O to 4,C1 C6 alkyl, CF3, phenyl, or substituted phenyl as defined above for R5 h tetrazole EMI77.1 wherein R7 is C1 C6 alkyl benzyl or phenyl j NR8R9 wherein R8 and R9 are independently selected from H, phenyl or substituted phenyl as defined above for P5 or C1 C4 alkyl, C1 C4 alkylamino alkyl, or may be joined through the N to form a heterocycloalkyl of 5 8 ring atoms k NHSO2R10 whereinR10 is OH, C1 C6 alkyl,C1 C6 alkoxy, phenyl orCF3 EMI77.2 m SOR11 wherein R11 isC1 C6 alkyl phenyl or substituted phenyl as defined above for R5, CH2 mCOOR6 wherein m is 1 to 6, CN, formyl or perfluoroC1 C4 alkyl n CONR8R9 o SO2NReR9 p SO2R13 wherein R13 is OH, H, C1 C6 alkyl, phenyl or substituted phenyl as defined above for R5, CH2 mCOOR6 wherein m is I to 6, CN or perfluoroC1 C4 alkyl q NO2 EMI78.1 u CN v NR15 R16 wherein R15 and R16 are such that HNP15R16 is an essential amino acid or 5 any two of R1, R2, R3 and P4 may be joined to form a fourth ring, which may be saturated or unsaturated, of five or six carbons and T is H, halogen or CF3 or a pharmaceutically acceptable salt of the compound df formula I and that the li poxygenase inhibitor or the salt thereof is used to produce a cytoprotective pharmaceutical composition which optionally furthermore contains a pharmaceutically acceptable carrier. 3. Use according to patent claim 2, characterized in that the cytoprotective active in gredient of formula I is 4 bromo 2,7 dimethoxy 3H phenothiazin 3 one or a salt thereof is used. 4. Use according to one of the patent claims 1 3, characterized in that the lipoxygenase inhibitor is used in an amount to produce a pharma ceutical composition with which the lipoxygenase inhibitor can be administered in an amount of 0,1 ,ug 500 mg of the lipogygenase inhibitor per kg body weight, preferably in an amount of lyug to 50 mg lipoxygenase inhibitor per kg body weight. 5. Use according to one of the patent claims 1 4, characterized in that the lipoxygenase inhibitor is used for the production of a cytopro tective pharmaceutical composition, which comprises as further component at least one non steroidal anti inflammatory drug and that the used lipoxygenase inhibitor reduces the undesirable side effects of the non steroidal anti inflammatory drug. 6. Use according to patent claim 5, characterized in that the weight ratio of the used lipoxygenase inhibitor to the used non steroidal anti inflammatory drug in the so produced pharmaceu tical composition is in the range of 1000 1 to 1 1000, preferably in the range of 200 1 to 1 200. 7. Process for the preparation of a cytoprotective pharmaceutical composition, characterized in that into a pharmaceutical composition there is incorporated a cytoprotective effective amount of at least one lipoxygenase inhibitor. 8. Process according to pater2 claim 7, characterized in that the incorporated lipoxygenase inhibitor is a compound of formula I EMI80.1 where in Xis in the 1 or 3 position and is O, S or NR wherein R is H, C1 C6 branched or linear alkyl, CN or phenyl Y is 0, Se, S, SO, S02 or NR and the broken line represents an optional double bond between the 1 and 2 or 2 and 3 position , R1, R2 R3 and R4 are independently selected from 1 hydrogen 2 alkyl having 1 6 carbon atoms 3 alkenyl having 2 6 carbon atoms 4 CH2 nM wherein n is 0 6 and M is a OR5 b halogen c CF3 d SR5 wherein R5 is H lower alkoxy lower alkyl lower acyloxy lower alkyl C1 C6 alkyl benzyl phenyl or substituted phenyl wherein the substituents are C1 C3 alkyl halogen, CN, CF3, COOP6, CH2COOR6, CH2 nNR8R9 wherein n is O to 2, C C alkoxy, OH, halo C1 C6 alkyl CH2 mCOOR6, wherein m is O to 6 and R6 is H, phenyl, or C C alkyl CN formyl perfluoroalkyl or CH2 R12 wherein n is O to 4, 12 is C1 C5 alkyl, dimethylamino or phenyl e phenyl or substituted phenyl as defined above for f COOR6 EMI82.1 wherein R14 is H, CH2 hCOOR6 wherein n is O to 4, C1 C6 alkyl, CF3, phenyl, or substituted phenyl as defined above for R5 h tetrazole EMI82.2 wherein P7 is C1 C6 alkyl, benzyl or phenyl j NR8R9 wherein R8 and Rg are independently selected from H, phenyl or substituted phenyl as defined above for R5, C1 C4 alkyl, C1 C4 alkylamino alkyl, or may be joined through the N to form a heterocycloalkyl of 5 8 ring atoms k NHSO2R10 wherein R10 is OH, C1 C6 alkyl, C1 C6 alkoxy, phenyl , or CF3 EMI82.3 m SOR11 wherein R11 is C1 C6 alkyl, phenyl or substituted phenyl as defined. above for R5, CH2 mCOOR6 wherein m is 1 to 6, CN, formyl or perfluoro C1 C4 alkyl, n CONR8R9 O SO2NR8R9 p SO2R13 wherein R13 is OH, C1 C6 alkyl, H, phenyl or substituted phenyl as defined above for R5, CH2 mCOOR6 wherein m is 1 to 6, CN, formyl or perfluoro C1 C4 alkyl, q NO2 EMI83.1 u CN v NR15 P16 wherein R15 and R16 aare such that HNR15R16 is an essential amino acid or 5 any two of R1, R2, R3 and R4 may be fused to add a fourth ring, which may be saturated or unsaturated, of five or six carbons and t is H,.halogen or CF3 or is a pharmaceutically acceptable salt of the compound of formula I. 9. Process according to patent claim 8, characterized in that the incorporated lipoxygenase inhibitor is 4 bromo 2 , 7 dimethoxy 311 pheno thiazin 3 one or a pharmaceutically acceptable salt tnereof. 10. Process according to one of the patent claims 7 9, characterized in that a cytoprotective pharmaceutical composition is prepared, which contains in addition to the cytoprotective amount of the lipoxygenase inhibitor at least one further pharmacologically active ingredient, preferably a second component having cytoprotective activity, a non steroidal anti inflammatory drug, a prostaglandin antagonist, a thromboxane antagonist, a histidine decarboxyase inhibitor, a H1 or H2 receptor antagonist and or a K t H ATPase inhibitor.

## Description
TITL OF THE INVENTION Use of LIPOXYGENASE INHIBITORS for the preparation of CYTOPROTECTIVE pharmaceutical compositions and process for the preparation of a cytoprotective pharmaceutical composition.BACKGROUND OF THE INVENTION The present invention concerns the use of LIPOXYGENASE INHIBITORS for the preparation of cytoprotective pharmaceutical compositions which contain ascytoprotective active component at least one lipoxygenase inhibitor. The present invention, furthermore, concerns a process for the preparation of a cytoprotective pharmaceutical composition which contains as cytoprotective active component at least one lipoxygenase inhibitor. The cytoprotective pharmaceutical compositioie which are produced according to the inventive use of at least lipoxygenase inhibitor or which are produced according to the inventive process by incorporating into said cytoprotective compositions as cytoprotective active component at least one lipoxygenase inhibitor, can be administered to a mammal, specially to man, for inducing cytoprotection. The pharmaceutical compositions accordingly are useful as inhibitors of mammalian leukotriene biosynthesis. The lipoxygenase inhibitors which are used according to the present invention are prior art pharmaceutically active ingredients which wore used in corresponding pharmaceutical compositions for treating allergic conditions, asthma, cardiova cular disorders, and inflammations. Prior to this invention, there was no evidence in the literature that the lipoxygenase inhibitors were cytoprotective.SUMMARY OF THE INVENTION The present invention concerns the use of lipoxygenase inhibitors for the preparation of cytoprotective pharmaceutical compositions which contain sscytoprotective active component at least one lipoxygenase inhibitor. The present invention, furthermore, concerns a process for the preparation of a cytoprotective pharmaceutical composition in which there is used as cytoprotective active component at least one lipoxygenase inhibitor. Preferred lipoxygenase inhibitors which are used according to the present invention are the compounds of formula I EMI3.1 or pharmaceutically acceptable salts of the compounds of formula I. According to a preferred embodiment of the invention, at least one lipoxygenase inhibitor is used for the preparation of a cytoprotective pharmaceutical composition which contains as cytoprotective active ingredient at least one lipogenase inhibitor and, furthermore, at least one further biologically active ingredient, for example a further cytoprotective active ingredient and or a non steroidal anti inflammatory drug.DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to the use of lipoxygenase inhibitors generally, and preferably compounds of formula I, as cytoprotective active components Dr producing cytoprotective active pharmaceutical compositions.The so produced cytoprotective pharmaceutical compositions may be used to treat or prevent disease states such as erosive gastritis erosive esophagitis inflammatory bowel disease ethanol induced hemorrhagic erosions hepatic ischemia noxious agent induced damage or necrosis of hepatic, pancreatic, renal, or myocardial tissue liver parenchymal damage caused by hepatoxic agents such as CCl4 and D galactosamine ischemic renal failure disease induced hepatic damage bile salt induced pancreatic or gastric damage trauma or stressinduced cell damage and glycerol induced renal failure. The cytoprotective activity of a compound may be observed in both animals and man by noting the increased resistance of the gastrointestinal mucosa to the noxious effects of strong irritants, for example, the ulcerogenic effects of aspirin or indomethacin. In addition to lessening the effect of non steroidal anti inflammatory drugs on the gastrointestinal tract, animal studies show that cytoprotective compounds will prevent gastric lesions induced by oral administration of strong acids, strong bases, ethanol, hypertonic saline solutions and the like. Two assays can be used to measure cytoprotective ability. These assays are A an ethanol induced lesion assay and B an indomethacin induced ulcer assay. A. Ethanol Induced Lesion Assay Twenty four hour fasted Sprague Dawley S.D. rats are perorally p.o. dosed with 1.0 ml absolute ethanol. Fifteen min. prior to ethanol administration, groups of rats each receive either an aqueous vehicle aqueous methylcellulose 5 wt. or the test compound at various doses perorally. One hour later, the animals are sacrificed and stomach ucosae are examined for resulting lesions. B. Indomethacin Induced Ulcer Assay Indomethacin, 10 mg kg p.o., is used to induce ulcers in 24 hr. fasted S.D. rats. Fifteen minutes prior to indomethacin administration, groups of rats each receive either an aqueous vehicle 5t wt. methylcellulose or the test compound at various doses perorally. Four hours later the animals are sacrificed and stomach mucosae are examined for resulting ulcers. As cytoprotective agents, the lipoxygenase inhibitors may generally be administered at a dosage range of 0.1 ug kg to 500 mg kg of body weight. The exact amount of inhibitor to be used will depend on, inter alia, whether it is being administered to heal damaged cells or to avoid future damage, on the nature of the damaged cells e.g., gastro intestinal ulcerations vs. nephrotic necrosis , and on the nature of the causative agent. The effective daily dosage level for compounds of Formula I inducing cytoprotection in mammals, especially humans, will range from about 1 ug kg to about 50 mg kg, preferably from about 10 vg kg to about 10 mg kg. The dosage may be administered in single or divided individual doses. Any suitable route of administration may be employed for providing a mammal, especially a human, with a cytoprotectively effective dosage of a lipoxygenase inhibitor. For example, oral, rectal, transdermal, parenteral, intramuscular, intraveneous and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules and the like. In practical use, ipoxygenase inhibitors can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or intravenous. In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. In addition to the common dosage forms set out above, the lipoxygenase inhibitors may also be administered by controlled release means and or delivery devices such as those described in U.S. Patent Nos. 3,845,770 3,916,899 3,536,809 3,598,123 3,630,200 and 4,008,719. In preparing suitable dosage forms, conventional compounding procedures and ingredients e.g. diluents, carriers, etc. may be used. The following are examples of representative pharmaceutical dosage forms fo Formula I compounds Injectable Suspension mg mLCompound of Formula I 0.7 350Methylcellulose 5.0 Tween 80 0.5Benzyl alcohol 9.0Methyl paraben 1.8Propyl paraben 0.2Water for injection to a total volume of 1 mlTablet mg tabletCompound of Formula I 0.7 350Microcrystalline Cellulose 0 349.8 Pr ov idone 14.0Microcrystalline Cellulose 90.0Pregelatinized Starch 43.5Magnesium Stearate 2 2.5 500Capsule mg capsuleCompound of Formula I 0.7 350Lactose Powder 248.5 598.3Magnesium Stearate 1 1.5 600 In addition to the lipoxygenase inhibitors, the pharmaceutical compositions can also contain other active ingredients, such as cyclooxygenase inhibitors or non steroidal anti inflammatory drugs NSAIDs .NSAIDs can be characterized into five groups 1 the propionic acid derivatives 2 the acetic acid derivatives 3 the fenamic acid derivatives 4 the biphenylcarboxylic acid derivatives and 5 the oxicams or a pharmaceutically acceptable salt thereof. The propionic acid derivatives which may be used comprise ibuprofen, ibuprufen aluminum, indoprufen, ketoprufen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid. Structurally related propionic acid derivatives having similar analgesic and anti inflammatory properties are also intended to be included in this group. Thus, propionic acid derivatives as defined herein are non narcotic analgesics nonsteroidal anti inflammatory drugs having a free CH CH3 COOH or CH2CH2COOH group which optionally can be in the form of a pharmaceutically acceptable salt group, e.g., CH CH3 COO Na or CH2CH2COO Na , typically attached directly or via a carbonyl function to a ring system, preferably to an aromatic ring system. The acetic acid derivatives which may be used comprise indomec3in, sulindac, tolmetin, zomepirac, diclofenac, fenclofenac, alclofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, and fenclozic acid. Structually related acetic acid derivatives having similar analgesic and antiinflammatory properties are also intended to be encompassed by this group. Thus, acetic acid derivatives as defined herein are non narcotic analgesics non steroidal antiinflammatory drugs having a free CH2COOH group which optionally can be in the form of a pharmaceutically acceptable salt group, e.g. CH2COONa , typically attached directly to a ring system, preferably to an aromatic or heteroaromatic ring system. The fenamic acid derivatives which may be used comprise mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid.Structurally related fenamic acid derivatives having similar analgesic and anti inflammatory properties are also intended to be encompassed by this group. Thus, fenamic acid derivatives as defined herein are non narcotic analgesics non steroidal antiinflammatory drugs which contain the basic structure EMI10.1 which can bear a variety of substituents and in which the free COOH group can be in the form of a pharmaceutically acceptable salt group, e.g., COO Na The biphenylcarboxylic acid derivatives which can be used comprise diflunisal and flufenisal. Structurally related biphenylcarboxylic acid derivatives having similar analgesic and anti inflammatory properties are also intended to be encompassed by this group. Thus, biphenylcarboxylic acid derivatives as defined herein are non narcotic analgesics nonsteroidal anti inflammatory drugs which contain the basic structure EMI11.1 which can bear a variety of substituents and in which the free COOH group can be in the form of a pharmaceutically acceptable salt group, e.g., COO Na , The oxicams which can be used in the present invention comprise piroxicam, sudoxicam, isoxicam and 4 hydroxyl 1,2 benzothiazine 1,1 dioxide 4 Nphenyl carboxamide. Structurally related oxicams having similar analgesic and anti inflammatory properties are also intended to be encompassed by this group. Thus, oxicams as defined herein are nonnarcotic analgesics non steroidal anti inflammatory drugs which have the general formula EMI11.2 wherein R is an aryl or heteroaryl ring system. The following NSAIDs may also be used acemetacin, alminoprofen, amfenac sodium, aminoprofen, anitrazafen, antrafenine, auranofin, bendazac lysinate, benzydamine, beprozin, broperamole, bufezolac, carprofen, cinmetacin, ciproquazone, clidanac, cloximate, dazidamine, deboxamet, delmetacin, detomidine, dexindoprofen, diacerein, di fisalamine, difenpyramide, emorfazone, enfenamic acid, enolicam epirizole, etersalate, etodolac, etofenamate, fanetizole mesylate, fenclofenac, fenclorac, fendosal, fenflumizole, fentiazac, feprazone, floctafenine, flunixin, flunoxaprofen, fluproquazone, fopirtoline, fosfosal, furcloprofen, furofenac, glucametacin, guaimesal, ibuproxam, isofezolac, isonixim, isoprofen, isoxepac, isoxicam, lefetamine HCl, leflunomide, lofemizole, lonazolac calcium, lotifazole, loxoprofen, lysin clonsxinate, meclofenamate sodium, meseclazone, miroprofen, nabumetone, nictindole, nimesulide, orpanoxin, oxametacin, oxapadol, oxaprozin, perisoxal citrate, pimeprofen, pimetacin, piproxen, pirazolac, pirfenidone, pirprofen, pranoprofen, proglumetacin maleate, proquazone, pyridoxiprofen, sudoxicam, suprofen, talmetacin, talniflumate, tenoxicam, thiazolinobutazone, thielavin B, tiaprofenic acid, tiaramide HCl, tiflamizole, timegadine, tioxaprofen, tolfenamic acid, tolpadol, tryptamid, ufenamate, and zidometacin. The following NSAIDs, designated by company code number, may also be used 4801565, AA861, AD1491, AD1590, AFP802, AFP860, AHR6293, AI77B, AP504, AU8Q01, BAYo8276, BPPC,BW540C, BW755C, CHINOIN 127, CN100, C0893XX, CPP, D10242, DKA9, DV17, EB382, EGYT2829, EL508, F1044, FZ, GP53633, GP650, GV3658, HG 3, ITC1, ITF, ITF182, KB1043, KC8973, KCNTEI6090, KME4, LA2851, LT696,LU20884, M7074, MED15, MG18311, MR714, MR897, MY309,N0164, ONO3144, PR823, PV102, PV102, Oz16, R830,RS2131, RU16029, RU26559, RUB265, SCR152, SH440, SIR133, SIR136, SIR92, SPAS510, SQ27239, ST281, SX1032, SY6001, SaH46798, TA60, TAI901, TEI615, TVX2706, TVX960, TZI615, U60257, UR2310, WY23205,WY41770, YM09561, YM13162, YS1033, and ZK31945. Finally, NSAIDs which may also be used include the salicylates, specifically aspirin, and the phenylbutazones, and pharmaceutically acceptable salts thereof. The lipoxygenase inhibitors may also be used in combination with leukotriene antagonists such as those disclosed in copendina applications U.S. SerialNos. 520,051 and 520,052, filed August 5, 1983 which are herein incorporated by reference and others known in the art such as those disclosed in European PatentApplication Nos. 56,172 and 61,800 and in U.K.Patent Specification No. 2,058,785. These pharmaceutical compositions may also contain as the second active ingredient, antihistaminic agents such as benadryl, dramamine, histadyl, phenergan and the like. Alternatively, they may include prostaglandin antagonists such as those disclosed in EuropeanPatent Application 11,067 or thromboxane antagonists such as those disclosed in U.S. 4,237,160. They may also contain histidine decarboxyase inhibitors such as cs fluoromethylhistidine, described in U.S.4,325,961. The lipoxygenase inhibitors may also be advantageously combined with an H1 or H2 receptor antagonist, such as for instance cimetidine, ranitidine, terfenadine, famotidine, aminothiadiazoles disclosed in EP 81102976.8 and like compounds, such as those disclosed in U.S. Patent Nos. 4,283,408 4,362,736 4,393,508 European Patent Application No. Ã•,696 and a pending application, U.S.S.N. 301,616, filed September 14, 1981. Each of these references is herein incorporated by reference. The pharmaceutical compositions may also contain a K H ATPase inhibitor such as omeprazole, disclosed inU.S. Pat. 4,255,431, and the like. The weight ratio of the lipoxygenase inhibitor to UNSAID or other active ingredient may be varied and may range from 1000 1 to 1 1000, preferably from 200 1 to 1 200, an effective amount of each compound being used. A further embodiment of this invention is a method of reducing the undesirable side effects ofNSAIDs which comprises the concomitant administration of a cytoprotectively effective amount of a lipoxygenase inhibitor, especially one of Formula I, and an NSAID. By concomitaijt is meant that the lipoxygenase inhibitor is administered from 30 minutes prior up to 30 minutes after administration of the NSAID. Preferably, the lipoxygenase inhibitor is administered prior to or simultaneously with theNSAID. In the compositions and methods of this invention, the compound 4 bromo 2,7 dimethoxy 3Hphenothiazin 3 one is particularly preferred. Specific compounds useful in this invention are those of Formula I, EMI15.1 where in X is in the 1 or 3 position and isO, S or NR wherein R is H, C1 C6 branched or linear alkyl, CN or phenyl Y is O, Se, S, SO, SO2 or NR and the broken line represents an optional double bond between the 1 and 2 or 2 and 3 position R1, R2, R3 and R4 are independently selected from 1 hydrogen 2 alkyl having 1 6 carbon atoms 3 alkenyl having 2 6 carbon atoms 4 tCH2 nM wherein n is 0 6 and M is a OR5 b halogen c CF3 d SR5 wherein R5 is H lower alkoxy lower alkyl lower acyloxy lower alkyl C1 C6 alkyl benzyl phenyl or substituted phenyl wherein the substituents are C1 C3 alkyl, halogen, CN, CF3, COOR6, CH2COOR6, CH2 nNR8R9 Wherein n is 0 to 2, C1 C3 alkoxy, OH, halo C1 C6 alkyl CH2 mCOOR6, wherein m is 0 to 6 and R6 is H, phenyl, or C1 C6 alkyl CN formyl perfluoroalkyl or CH2 R12 wherein n is 0 to 4, R12 is C1 C5 alkyl, dimethylamino or phenyl e phenyl or substituted phenyl as defined above for R5 f COOR6 EMI16.1 wherein R14 is H, CH2 nCOOR6 wherein n is O to 4, C1 C6 alkyl, CF3, phenyl, or substituted phenyl as defined above for R5 h tetrazole EMI17.1 wherein R7 is C1 Cs alkyl, benzyl or phenyl j NR8R9 wherein R8 and R9 are independently selected from H, phenyl or substituted phenyl as defined above for R5, C1 C4 alkyl, C1 C4 alkylamino alkyl, or may be joined through the N to form a heterocycloalkyl of 5 8 ring atoms k NHSO2Rlo wherein R10 is OH, C1 C6 alkyl, C1 C6 alkoxy, phenyl, or CF3 EMI17.2 m SOR11 wherein R11 is C1 C6 alkyl, phenyl or substituted phenyl as defined above for R5, CH2 mCOOR6 wherein m is 1 to 6, CN, formyl or perfluoro C1 C4 alkyl m CONR8R9 o SO2NR8R9 p SO2R13 w rein R13 is OH, C1 C6 alkyl, H, phenyl or substituted phenyl as defined above for R5, CH2 mCOOR6 wherein m is 1 to 6, CN, formyl or perfluoro C1 C4 alkyl q NO2 EMI18.1 u CN v NR15 R16 wherein R15 and R16 aare such that HNR15R16 is an essential amino acid or 5 any two of R1, R2, R3 and R4 may be fused to add a fourth ring, which may be saturated or unsaturated, of five or siv carbons and t is H, halogen or CF3. The numbers surrounding Formula I designate the substituent positions. T, R1, R2, R3 andR4 may be positioned anywhere in the structure.R1, R2, R3 and R4 may be joined, e.g. as CH2 34 to add a fourth ring to the basic three ring structure. This fourth ring may have five or six carbon atoms and may be saturated or unsaturatec For example, compounds of Formula II may be prepared by linking two of the substituent groups R1, R2, R3, R4 EMI19.1 wherein Z may be CH, CH2 or a bond, the broken lines represent optional double bonds and R represents the substituent groups of Formula I R1,R2, R3, R4 and or T not used to create the fourth ring. The preferred compounds of Formula II have the structure II a EMI19.2 wherein Ra is selected from hydrogen, halogen F,Br, C1, I , CH3, CF3, CORd, NHRd, SRd andORd Rb is selected from hydrogen, halogen F,Br, C1, I , CH3, CF3, CH2OH, ORd, SRd,CORd, COORd, CH2COORd and CH CH3 COORd Rdis hydrogen, phenyl, C1 4 straight or branched alkyl Rc is selected from hydrogen or ORd, and Y is selected from 0, S, SO or SO2. Where possible, appropriate pharmaceutically acceptable salts of Formula I are included e.g., carboxylic or mineral acid addition salts whereFormula I is basic and metal salts e.g. Na, K, NH4 where Formula I is acidic. The term alkyl, unless indicated otherwise, includes straight chain branched chain and cycloalkyl groups. The term halogen or halo, unless otherwise indicated, includes C1, Br, I and F. A group of preferred compositions contain a compound of the Formula EMI20.1 More preferred Formula I a compounds are those wherein X is O or NH and Y is S, O, SO orSO2. Still more preferred I a compounds are those having the Formula EMI20.2 wherein a T, R3 and R2 are hydrogens, b T, R1, R2 are hydrogens, c T, R3 and R4 are hydrogens, d T, R1, R2 R3 are hydrogens or e T, R3 R4, R2 are hydrogens.wherein R1, R2, R3, R4 and T are as defined for Formula I. Another group of preferred compositions contain compounds of the Formula I b EMI21.1 More preferred compounds of Formula Ib are those having the Formula wherein X is O or NH and Y is Q, S, SO, SO2. Still more preferred compounds of Formula I b are those of the Formula I c EMI21.2 wherein a T, R3 and R2 are hydrogens, b T, R1, R2 are hydrogens, c T, R3 and R4 are hydrogens, d T, Rl, R2 R3 are hydrogens, e T, R3 R4, R2 are hydrogens, f T, R3 and R4 are hydrogens and R1 is in position 4, g T, R3, R2 are hydrogens and R1 is in position 4, h T, R4, R3 R2 are hydrogens and R1 is in position 4, i R2 and R3 are hydrogens, j R1 and R2 are hydrogens, k R3 and R4 are hydrogens, 1 R2 R3 are hydrogens and T is in position 4, m T and R3 are hydrogens and R2 is in position 4, n T and R3 are hydrogens and R1 is in position 4 and R2 is in position 2, o T and R3 are hydrogens and R4 is in position 7, R2 is in position 4 and R1 is in position 2. p T is hydrogen, R1, R2, R3, and R4 are in positions 1, 2, 4 and 7, respectfully. A particularly preferred series of Formula I c compounds are those in which n. 0 or 1 in the unit CH2 nM Examples of Formula I compounds useful in the present compositions are tabulated below. In each of the tables the numbers preceding the T and the R1 R4 definitions indicate the substituent position in the structure. TABLE 1Compounds of the Formula EMI23.1 EMI23.2 tb Number SEP Y SEP X SEP R1 SEP R2 SEP R3 SEP R SEP T tb SEP 1 SEP 0 SEP 0 SEP 2 t Bu SEP St Bu SEP 4 t Bu SEP 6 t Bu SEP H tb SEP 2 SEP 0 SEP 0 SEP 2 t Bu SEP H SEP 4 e SEP H SEP H tb SEP 3 SEP F SEP 3,s,o, tb SEP Se,SO SEP or tb SEP 5 2 SEP SEP 2 C1 SEP H SEP H SEP H SEP H tb SEP 4 SEP SEP O SEP t SCF3 SEP H SEP H SEP H SEP H tb SEP 5 SEP SEP 0 SEP 2 SCO2H SEP H SEP H SEP H SEP H tb SEP 6 SEP SEP 0 SEP 241 SEP H SEP H SEP H SEP H tb SEP 7 SEP SEP O SEP H SEP 3 C02Et SEP H SEP H SEP H tb SEP N SEP SEP O SEP H SEP NC1 SEP H SEP H SEP H tb SEP 9 SEP SEP O SEP H SEP H SEP 4 C1 SEP H SEP H tb SEP 10 SEP SEP O SEP H SEP H SEP 2 SEP 3 SEP H SEP H tb SEP 11 SEP SEP 0 SEP 2 C1 SEP H SEP bC1 SEP H SEP H tb SEP 12 SEP SEP NH SEP t C1 SEP H SEP 4 SEP C1 SEP H SEP I tb SEP 13 SEP NH SEP H SEP H SEP H SEP H SEP H tb SEP 14 SEP FCtI SEP O SEP ZC1 SEP H SEP 4C1 SEP H SEP H tb TABLE 1 CONT DNumber Y X R1 R2 R3 R4 T 15 S O H H H H H 16 5 O 2C1 3 C1 4 C1 7 C1 9 C1 17 S O 2 Br 3 Br 4Br 7 Br 9 Br 18 S O H H H 7 SO2CH3 H 19 S O 2 C1 H 4 SO2CH3 H H 20 5 O 2 F H 4 Cl H H 21 S 0 2 Br H H H H 22 S 0 2 CF3 H H H H 23 S 0 2 SCF3 H H H H 24 S 0 2 502CF3 H H H H 25 S 0 H 3 C1 H H H 26 5 0 H CO2Et H H H 27 5 O H 3 CO2H H H H 28 S O H 3 CN H H H 29 S 0 H 3 SCF3 H H H 30 S O H H 4 C1 H H 31 S O H H 4 SCF3 H H 32 5 O H H 4 C1 H H 33 5 0 2 Br H 4 Br H H 34 S 0 2 C1 H H B CN H 35 5 0 2 C1 H H B CN H 36 5 0 2 C1 H H B CO2Et H 37 5 0 2 C1 H H B Cf3 H 38 S 0 2 C1 H H 7 SO2CH3 H 39 S O H 3 CONHe2 H H H 40 5 0 2 C1 H H 7 OCH3 H TABLE 1 CONT DEMI25.1 tb SEP R SEP T tb Ntiiter SEP V SEP X SEP R1 SEP 4 tb SEP 41 SEP 5 SEP 0 SEP 2 StC 2H SEP H SEP H SEP H SEP H tb SEP 2 tb SEP 42 SEP S SEP 0 SEP 2SO2CH3 SEP H SEP H SEP H SEP H tb SEP 43 SEP 5 SEP 0 SEP 2 CH2CH 12 SEP H SEP CH2 SEP H SEP H tb SEP 44 SEP S SEP 0 SEP H SEP N CH3 2 SEP H SEP H SEP H tb SEP 45 SEP 5 SEP 0 SEP H SEP H SEP 4 SEP C1 SEP 7 SC6H6 SEP H tb SEP 46 SEP 5 SEP 0 SEP 2CH2CO2H SEP H SEP H SEP H SEP H tb SEP 47 SEP S SEP 0 SEP 2 C1 SEP H SEP eSCH2Co2H SEP H SEP H tb SEP 48 SEP 5 SEP 0 SEP 2m3 SEP H SEP H SEP 7 SEP OCH3 SEP H tb SEP 49 SEP S SEP O SEP H SEP H SEP 44C6H6 SEP 7o3 SEP H tb SEP 50 SEP S SEP NH SEP 2C1 SEP H SEP 4 C1 SEP H SEP H tb SEP 51 SEP S SEP NH SEP H SEP 3Mi CH3 2 SEP 2 SEP H SEP N SEP H tb SEP 52 SEP S SEP NH SEP 2 SCH3 SEP H SEP ISO43 SEP H SEP H tb SEP 53 SEP S SEP 0 SEP H SEP H SEP H SEP H SEP H tb SEP 54 SEP 5 SEP NH SEP H SEP H SEP H SEP H SEP H tb SEP 55 SEP 5 SEP NH.HC1 SEP H SEP H SEP H SEP H SEP H tb SEP 56 SEP S SEP 0 SEP H SEP H SEP H SEP H SEP H tb SEP 57 SEP 0 SEP 0 SEP H SEP H SEP H SEP H SEP H tb SEP 58 SEP 0 SEP NH SEP H SEP H SEP H SEP H SEP H tb SEP 59 SEP 0 SEP S SEP H SEP H SEP H SEP H SEP H tb SEP 60 SEP 0 SEP NH.HCl SEP H SEP H SEP H SEP H SEP H tb SEP 61 SEP Se SEP 0 SEP H SEP H SEP H SEP H SEP H tb SEP 62 SEP Se SEP NH SEP H SEP H SEP H SEP H SEP H tb SEP 63 SEP S SEP S SEP H SEP H SEP H SEP H SEP H tb SEP 64 SEP t SEP NH.HCl SEP H SEP H SEP H SEP H SEP H tb SEP 65 SEP SEP S SEP H SEP H SEP H SEP H SEP H tb SEP 66 SEP 0 SEP 0 SEP 4C1 SEP H SEP H SEP H SEP H tb TABLE I CONT DNumber Y X R1 R2 R3 R4 I 67 0 0 4 Cl H 7 OHe.H H 68 0 0 4 Me H H H H 69 0 0 H 2 C7 H H H 70 0 O 4 c 2 S pPAA H H H 71 5e C 4 Cl H H H H 72 Se 0 4 C1 H 7 OHe H H 73 Se 0 4 Ne H H H H 74 Se O 4 Cl 2 S pPM H H H 75 N CH3 O 4 C1 H H H H 76 N C6H6 4 C1 H 7 OHe H H 77 N H O 4 C1 2 5 pPM H H H 78 5 O 4 Cl H H H H 79 SO O H H H H H 80 SO2 0 H H H H H 81 SO2 O 4 C1 H H H H 82 N Me O H H H H H S3 N Ha O 4 Cl H H H H 84 N Me 0 4 C1 H 7 OMe H H 85 NMe O 4 Br H 7 OMe Z OMe H 86 NCH O 4 Br H 7 OMe Z OMe H 87 MCH C 4 Cl H H H H 88 NH O 2 Cl H H H H 89 NH O 4 C1 H H H H 90 S 0 2 t Bu 4 t Bu H H H 91 5 C 2 t Bu 4 t Bu 9 OMe H H 92 S O Z t Bu 4 t Bu 7 F H H 93 5 0 2 t Bu 4 t Bu 7 Me H H 94 S O 2 T Bu 4 t Bu 7 SMa H H p PM para phenylacetic acid TABLE 2Compounds of the FormulaEMI27.1 Number Y R1 R2 R3 R4 I 95 S H H H H H 96 S 2 C1 H H H H 97 S H H 6 C H H 98 5 H H 7 C1 H H 99 5 H H 8 Cl H H 100 S H H 9 Cl H H 101 S 1 Cl H H H H 102 S 1 Cl 4 C1 H H H 103 S 2 Cl 4 Cl H H l Cl 104 S 2 N Se z H H H H 105 S Z SMe H H H H 106 S 2 S pPAt H H H H 107 S Z C O CH3 H H H H 108 S 2 OMe H H H H 109 S H H H 7 CH2C02H H 110 S H H H 8 CH COOH H 111 S H Z SO3 H H H 112 5 Z N Me 2 H H H H 113 S 2 SMe H H H H 114 S 2 C O CH3 H H H H TABLE 2 CONT DNumber Y R1 R2 R3 R4 T 5 5 2 OMe H H H H 116 S 2 CH2CO2H H H H H 117 S 2 CH CH3 CO2H H H H H 118 S 4 CH2COOH H H H H 119 S 4 CH CH3 CO2H H H H H 120 S H H 7 OH 6 propyl H 121 S 4 Cl H H H H 122 5 4 F H H H H 123 S 4 F H 7 C1 H H 124 S 4 Et H H H H 125 5 4 Et H 7 OMe H H 126 5 4 Et H 7 Cl H H 127 5 4 C1 H 7 OMe H H 128 S OMe H 7 C1 H H 129 5 4 C1 H 6 Cl H H 120 S 4 Cl H S Cl H H 131 S 4 Cl H 9 Cl H H 132 5 4 C1 H 5 OMe H H 133 S 4 Cl H 8 OHe H H 134 S 4 Cl H 9 Et H H 135 S 4 Cl H 6 Et H H 136 S 4 C1 H 7 Et H H 137 S 4 C1 H 8 Et H H 138 5 4 Cl l Et H H H 139 S 4 C1 2 Et H H H 140 5 4 C1 1 CH2COOH H H H 14 S 4 Cl 2 CH2COOH H H H 142 5 4 C1 H 6 CH2COOCH H H TABLE 2 CONT DNumber Y R1 R2 R3 R4 T 143 S 4 C1 H 7 CH2COOOH H H 144 S 4 C1 H 8 CH2COOCH H H 145 5 4 C1 2 N Me 2 H H H 146 S 4 Cl 1 N Me 2 H H H 147 S 4 Cl 2 N Me 2 7 OMe H H 148 S 4 Cl 2 N Me 2 7 Cl H H 149 S 4 Cl 2 SMe H H H 150 S 4 Cl 2 SCH2COOH H H H 151 S 4 C1 Z S pPM H H H 152 S 4 Cl 1 SpPM H H H 153 S 4 C1 2 S pPAA 7 OMe H H 154 S 4 Cl 2 So3H H H H 155 S 4 C1 2 OHe H H H 156 S 4 C1 2 OMe 7 C1 H H 157 5 4 Cl H 7F H H 158 5 case H 7 OMe H H 159 S 4 OMe H 7 Me H H 160 S 4OMe 2 SMe H H H 161 S 4 Se H H H H 162 5 4 Br H H H H 163 5 4 1 H H H H 154 S 4 Br H 7 OMe H H 165 5 4 1 H 7 OMe H H 166 S 4 Br Z Me H H H 167 S 4 l 2 Me H H H 168 S 4 C1 H 7 8 CH2 4 H 169 S 4 C1 H 7 8 CH2 3 H 170 5 4 Br 2 OMe 7 OMe H H TABLE 2 CONT DNumber Y R1 R2 R3 R4 T 171 S 2 OMe 7 OMe H H H 172 S 1 OMe 7 OMe H H H 173 S 2 OMe 7 OMe H H 1 Br 174 S 1 OMe 7 OMe H H 2 Br 175 5 1 OMe 7 OMe H H 4 Br 176 S 1 OMe 7 OMe H H 2 C1 177 S 1 OMe 7 OMe H H 4 Cl 178 S 2 OMe 7 OMe H H 1 Cl 179 5 2 OMe 7 OMe H H 4 C1 180 S 2 OEt 7 OEt H H 1 Br 181 S 2 OEt 7 OEt H H 4 Br 182 S 2 OEt 7 OEt H H 1 Cl 183 S 2 OEt 7 OEt H H 4 Cl 184 S 2 OMe 7 OMe 8 OMe H 1 Br 185 S 2 OMe 7 OMe 8 OMe H 4 Br 186 S 2 OMe 7 OMe H H 4 F 187 S 2 OMe 7 OMe H H 4 CF3 188 S 2 OMe 7 OEt H H 4 Br 189 S 2 OMe 7 OEt H H 4 Cl 190 S 2 OMe 7 OEt H H 4 F 191 S 2 OMe 7 OEt H H 4 CF3 192 S 2 OEt 7 OMe H H 4 Br 193 S 2 OEt 7 OMe H H 4 Cl 194 S 2 OEt 7 OMe H H 4 F 195 S 2 OEt 7 OMe H H 4 CF3 196 S 1 OMe 7 OMe 7 OMe H 4 Br 197 S 1 OMe 7 OMe H H 198 S 1 OMe 7 OMe H H 1 Br 199 O Same as Numbers 90 198 TABLE 2 CONT DEMI31.1 tb Nurber SEP r SEP R1 SEP R SEP R SEP R SEP T tb SEP 1 SEP 4 tb 200 SEP sO SEP 4 OH SEP H SEP H SEP H SEP H tb SEP 2 tb 201 SEP sO2 SEP 1PIe SEP SEP 2 e SEP 4 CH3 SEP H SEP H tb 202 SEP 5 2 SEP 2 OYe SEP 7 OMe SEP 40H SEP H SEP H tb 203 SEP 5 2 SEP 2 ONe SEP 4 OH SEP H SEP H SEP H tb 204 SEP 5 2 SEP l tMS SEP 4 OH SEP H SEP H SEP H tb 205 SEP 2 SEP 2 e SEP 4 OH SEP H SEP H SEP H tb 206 SEP S02 SEP 2 C1 SEP 4 OH SEP H SEP H SEP H tb 207 SEP S02 SEP 2 OEt SEP 70Et SEP 4 OH SEP H SEP H tb 208 SEP sO2 SEP 2 SD2He SEP 4 OH SEP H SEP H SEP H tb 209 SEP 5 2 SEP 4 OHe SEP H SEP H SEP H SEP H tb 210 SEP S02 SEP 2 ONe SEP 4 Ore SEP 7 ore SEP H SEP H tb 211 SEP O SEP l C02H SEP 4 OH SEP 7 hrk2 SEP H SEP H tb 212 SEP 0 SEP l Cl SEP 2 C1 SEP 4C1 SEP H SEP 7 C1 tb 213 SEP 5 SEP 9 OHe SEP H SEP H SEP H SEP H tb 214 SEP S SEP 2 SEP H SEP H SEP H SEP H tb 215 SEP 5 SEP 2 me SEP ICr SEP H SEP H SEP H tb 216 SEP S SEP 1 One SEP Z Or e SEP Ce SEP H SEP H tb 217 SEP S SEP 4 OMe SEP H SEP H SEP H SEP H tb 218 SEP S SEP l OMe SEP 7 OMe SEP H SEP H SEP 4Br tb 219 SEP 5 SEP l Ore SEP 7 ore SEP 2C1 SEP H SEP 4 C1 tb 220 SEP 5 SEP lMe SEP 7 OHe SEP H SEP H SEP 4C1 tb 221 SEP 5 SEP 2 N e SEP 7OMe SEP H SEP H SEP H tb SEP I tb SEP Im tb SEP 222 SEP S SEP 2 N SEP t SEP 7 SEP Ae SEP H SEP H SEP 4Br tb SEP U tb SEP 223 SEP 5 2 SEP 2 0me SEP 4 OH SEP 7 SEP H SEP H tb TABLE 2 CONT DEMI32.1 tb Number SEP V SEP R1 SEP R4 SEP T tb 224 SEP 5 2 SEP l HHPr SEP MHPr SEP H SEP H SEP H tb SEP So tb SEP 2 tb SEP fN SEP r tb 225 SEP S02 SEP 1 N SEP NMe SEP 4 N SEP Fte SEP H SEP N tb SEP Hne SEP 1 SEP H SEP H tb SEP ,m tb 226 SEP S02 SEP 2 OHe SEP 4 9 SEP 7 SEP 7 OYe SEP H SEP H tb 227 SEP 502 SEP 2 OZe SEP 7 OYe SEP H SEP H SEP H tb 228 SEP 2 SEP 4 SEP NHpr SEP 4 NHPr SEP H SEP H tb 229 SEP 5 SEP l NHPt SEP 4 NHPr SEP H SEP H SEP H tb 230 SEP S SEP l NHPr SEP 4 HHPr SEP 7 ONe SEP H SEP H tb 231 SEP 5 SEP l num ffPr SEP 4 NHPr SEP H SEP H SEP H tb 232 SEP 5 SEP 2 HHPr SEP NHPr SEP 7 SEP H SEP H tb 233 SEP 5 SEP 2 OPe SEP 4 NH2 SEP 2 SEP H SEP H tb 234 SEP 5 SEP 2 OMe SEP 4 SHPr SEP 7were SEP H SEP H tb 235 SEP 0 SEP l Offe SEP bC1 SEP t razz SEP H SEP H tb 236 SEP 0 SEP l ONe SEP 4 8r SEP 7 OPe SEP H SEP H tb 237 SEP 0 SEP 1 1fr SEP 4 NHPr SEP H SEP H SEP H tb 238 SEP 2 SEP 1 SEP 4 CN SEP 7 OMe SEP H SEP H tb 239 SEP 5 2 SEP 2 0Fe SEP 4 HHCH2Co2R SEP 7 C le SEP H SEP H tb 240 SEP 5 2 SEP 2 OMe SEP 4 5 7 Bu SEP 7love SEP H SEP H tb 241 SEP 2 SEP Z OZe SEP 4 CH2CO SEP t SEP 7 ONe SEP H SEP H tb 242 SEP 502 SEP Z OHe SEP 4 S02 SEP 7 me SEP H SEP H tb 243 SEP 5 SEP 2 S n Bu SEP H SEP H SEP H SEP H tb 244 SEP 5 SEP 4 S n Du SEP H SEP H SEP H SEP H tb 245 SEP S, SEP 5 SEP 2one SEP 4 S n 3u SEP H SEP H SEP H tb R is H or C1C4 alkyl. TABLE 2 CONT DNumber Y R1 R2 R3 R4 T 246 S 2 OMe 7 Me H H 4 Br 247 S 2 OMe 7 CF3 H H 4 Br 248 S 2 OMe 7 F H H 4 Br 249 S 2 OMe 7 Cl H H 4 Br 250 S 2 OMe 7 Br H H 4 Br 251 S 2 OMe 7 NMe H H 4 Br 252 S 2 OMe 7 SMe H H 4 Br 253 S 2 OMe 7 SO2Me H H 4 Br 254 S 2 OMe 70 Ph H H 4 Br 255 S 1 Me H H H H 256 S 2 Me H H H H 257 S 2 OEt H H H H 258 S 7 Cl H H H H 259 S 9 C1 H H H H 260 S 7 F H H H H 261 S 7 e H H H H 262 5 7 OMe H H H H 263 5 2 Cl H H H H 264 S 1 Me 7 Me H H H 265 S 1 Me 7 Ne H H H 266 S 2 OMe 7 OEt H H H 267 0 2 NH2 H H H H 268 0 7 OH H H H H 269 0 COMe H H N H 270 SO2 2 OMe 7 OMe H H 4 Br 271 5 2 NHPr 4NHPr H H H 272 S 2 Cl H H H 4 Cl 273 S like 7 Me H H 4 Cl TABLE 3Compounds of the FormulaEMI34.1 Example Y X R3 R4 T 1 O O H H H 2 S O H H H 3 SO O H H H 4 SO2 O H H H 5 SO O H H 6 C1 6 S O 6 COCH3 H H 7 S O 6 CH3 H H 8 502 O 6 OH H H 9 SO2 O 6 OMe H H 10 S 0 9 OMe H H 11 S 0 6 OH H H 12 S 0 6 OMe H H 13 S O 6 NHCOMe H H 14 S O 6 NHPh H H 15 S O H H 6 Br 16 S 0 6 NHMe H H 17 S O 6 NH t Bu H H 18 S O 6 NH COMe H 9 C1 19 S O 6 NH COMe 9 OMe H TABLE 3 CONT1D Example Y X R3 R4 T 20 S 0 6 NHPh p Br H 9 C1 21 0 0 H H H 6 C1 22 0 O H H 6 Br 23 0 0 9 OMe H 6 Br 24 0 0 9 OMe 6 NHPr H 25 S 0 6 CF3 H H 26 S O 6 S n Bu H H 27 S O 6 OMe H 9 C1 28 S O 9 OMe H 6 C1 29 S O 6 OMe 9 OMe H 30 S O 6 C1 9 Me ll Br 31 S O 6 NHPh 9 Me ll Br 32 S O 6 Me H H 33 0 NH 9 NMe2 10 Me H 34 O NH 9 N Et 2 H H In addition to the specific compounds described above encompassed by Formula I, these further compounds of Formula I are also within the scope of the invention EMI35.1 Tables 4, 5 and 6 further describe these compounds TABLE 4 FORMULA I COMPOUNDEMI36.1 Y Ra Rb Rc Rd Re Rf RgS H H CF3 H H H HS H CF3 CF3 H H H HS CF3 H H H H H HS H F H H H H HS H SCH3 H H H H HS H OH H H H H HS H H F H H H HS H H OCH3 H H H HS H H SCF3 H H H HS H H CN H H H HS H H CHO H H H HS H H COCF3 H H H HS H H H H SCH3 H HS H H H H OCH3 H HS H H H H CO2CH3 H HS H H H H CO2H H HS H H H H CH H HS H H H H CHO H HS H H H H CONH2 H H TABLE 4 CONT D Y Ra Rb Rc Rd Re Rf R S H H H H CH2OH H H S H H H H CF3 H H S CH3 H Cl H H H H S H CH3 Cl H H H H S H H Cl H F H H S H Cl Cl H F H H S H CH3 H H F H H S CH3 H H H F H H S H H Cl H Ore H H S H H Cl H CF3 H H S H H Cl H CO2Na H H S H H Cl H CO2H H H S H H Cl H CH H HS H H Cl H CHO H H S H H Cl H CONH2 H H S H H Cl H CH2OH H H S H H OCH3 H Cl H H S H H CF3 H Cl H H S H OEt Cl H H H H S H OiPr H H H H H S Ore H Cl H H H H S OEt H Cl H H H H S H OiPr Cl H H H H S H O benzyl Cl H H H H S H OCH3 Cl H H H H S H OEt H H F H H S H OEt t H H CH3 H H TABLE 4 CONT D Y Ra Rb Rc Rd Re Rf Rg S H OEt Cl .H F H H S H OEt Cl H CH3 H HS H H Cl H CH3 H HS H CH3 I H H H HS H CH3 Br H H H HCH3 H H H CH3 H HS H CH3 H H CH3 H HS CH3 H Cl H CH3 H HS H CH3 Cl H CH3 H HS Cl H Cl H F H H H Ore Br H OMe H H N OMe Cl H OMe H HS H OEt t Br H OEt H HS H OEt Cl H OEt H HS H OMe Cl H OEt H HS H OMe H H Se H HO H OMe Br H OMe H HO H OMe Cl H OMe H HO H H Cl H H o H HSO2 H H OH H H H HSO2 H OMe OH H OMe H HSO2 OMe OMe Me H H H HSO2 H H OMe H H H HH OMe OMe H OMe H HS H H H H H H OCH3S H OCH3 H H F H HS H OCH3 OCH3 H H H H TABLE 4 CONT DEMI39.1 tb V SEP R SEP R SEP SEP R SEP Rd SEP R SEP W SEP A SEP R tb SEP a SEP L SEP d SEP 5 SEP f SEP T tb S SEP OCH3 SEP OCH3 SEP Xe SEP H SEP H SEP H SEP H tb S SEP H SEP H SEP COCK SEP H SEP H SEP H SEP H tb SEP 3 tb S SEP OCH3 SEP H SEP Br SEP H SEP OCH3 SEP H SEP H tb S SEP OCH3 SEP Cl SEP C1 SEP H SEP OCH3 SEP H SEP H tb S SEP OCH3 SEP H SEP C1 SEP H SEP OCH3H SEP H SEP H tb S SEP N SEP N NCH SEP SEP H SEP H SEP OCH3 SEP H SEP H tb SEP J SEP 3 tb S SEP H SEP N SEP n SEP Br SEP B SEP H SEP OCHs SEP H SEP H tb SEP vi SEP 3 tb 2 SEP H SEP OCH3 SEP OH SEP H SEP OONX SEP H SEP H SEP H tb 5 2 SEP NHPr SEP H SEP NHPr SEP H SEP H SEP H SEP N tb SEP 7 SEP Im tb SO SEP N SEP CH3 SEP H SEP iNOH SEP H SEP H SEP H SEP H tb SEP 2 SEP J3 tb 502 SEP II SEP OOH3 SEP NNCN3 SEP H SEP OCH3 SEP H SEP H tb SEP 3 SEP 3 tb 5 2 SEP H SEP OCH3 SEP Br SEP H SEP OCH3 SEP H SEP H tb S SEP NHPr SEP H SEP NHPr SEP H SEP H SEP H SEP II tb S SEP NHPr SEP H SEP HHPr SEP H SEP oCH3 SEP H SEP H tb TABLE 4 CONT DY Ra Rb Rc Rd Re Rf RgS H HNPr NHPr H H H H S H NHPr NHPr H OCH3 H H S H OCH3 NH2 H OCH3 H H S H OCH3 NHPr H OCH3 H H SO2 H OCH3 NHPr H OCH3 H H O OCH H Cl H OCH3 H H O OCH H Br H OCH3 H H O NHPr H NHPr H H H H SO2 H OCH3 CN H OCH3 H H SO2 H OCH3 NHCH2CO2R H OCH3 H H SO2 H OCH3 S n Bu H OCH3 H H SO2 H OCH3 CH2CO2R H OCH3 H H SO2 H OCH3 SO2CH3 H OCH3 H H 5 H 5 n Bu H H H H H S H H S n Bu H H H H S H CH3 S n Bu H H H H S H OMe Br H CF3 H H S H one Br H F H H S H OMe Br H Cl H H 5 H OMe Br H Br H H S H OMe Br H NMe H H S H OMe Br H SMe H H S H OMe Br H SO2Me H H S H OMe Br H Ph H H S H H H Cl OMe H H S H OMe Br H Me H H R is H or C1 C4 alkyl. Table 5 describes the compounds useful in the present investion having four rings. TABLE 5 COMPUNDS OF FORMULA IIEMI41.1 Y R1 R2 R3 R4S H H S n CH4H9 HS OH H CH3 HS OCH3 H CH3 HS H H F HS H H CF3 HS H H Cl CF3S H H Cl SCH3S H H Br ClS H H CH3 BrS H H P BrS H H COCH3 ClS H H CF3 CH3S H H S n C4H9 CH3S H H CF ClS H H Cl CH2COOR TABLE 5 CONT DEMI42.1 tb Y SEP R1 SEP R SEP R tb SEP 3 SEP 4 tb S SEP H SEP H SEP Cl SEP CH He C02B tb S SEP H SEP H SEP C1 SEP COCH3 tb S SEP H SEP H SEP H SEP C1 tb S SEP H SEP H SEP H SEP Br tb S SEP H SEP H SEP H SEP F tb S SEP H SEP H SEP H SEP CF3 tb S SEP H SEP H SEP H SEP CH3 tb S SEP H SEP H SEP H SEP CH20H tb S SEP H SEP H SEP H SEP ocH3 tb S SEP H SEP H SEP H SEP SCH3 tb S SEP H SEP H SEP H SEP COOT tb S SEP H SEP H SEP H SEP CH2C02 SEP R tb S SEP H SEP H SEP H SEP CH Me C02R tb S02 SEP H SEP H SEP NHPr SEP H tb 502 SEP H SEP H SEP N SEP n SEP U CH3 SEP H tb S02 SEP H SEP H SEP NH2 SEP H tb 2 SEP H SEP H SEP NHPr SEP OCH3 tb S SEP 1,4 dihydro SEP H tb S SEP H SEP H SEP NHPr SEP OCH3 tb o SEP H SEP H SEP C1 SEP H tb o SEP H SEP H SEP Br SEP H tb o SEP H SEP H SEP Br SEP OCH3 tb o SEP H SEP H SEP NHPr SEP OCH3 tb R is H or C1 4 alkyl Table 6 describes additional compounds useful in the present invention. TABLE 6 COMPOUNDS OF FORMULA IEMI43.1 Ra Rb Rc Rd t Bu t Bu H H t Bu t Bu F H t Bu t Bu Me H t Bu t Bu SMe H t Bu t Bu H OMe Formula I includes both novel and known compounds. These compounds may be prepared by any process available to the skilled artisan. One such process for compounds where X s involves the oxidation of the appropriate phenothiazine as illustrated by the following equations.EMI44.1 Various oxidizing agents and systems are taught in the art, e.g. PbO2, HNO3, K2Cr207,K2Cr207, iodine, FeC33 and the like. Another process useful for preparing someFormula I compounds containing halogen substituents is by direct halogenation of an appropriate phenothiazone or analog thereof as illustrated by the following equation.EMI44.2 Still another process useful for preparing many of the Formula I compounds is by the reaction of an appropriate aniline with an appropriate quinone as illustrated by the following equation EMI45.1 This general process is described in the literature. A specific process for preparing the intermediate phenothiazin 3 one is illustrated by the following equation EMI45.2 The process requires the use of 2 moles of quinone per mole of aniline. Any suitable solvent may be used.Example of such solvents are acetic acid, lower alkanols, acetic acid H20, loweralkanol water, other polar solvents and the like. A preferred solvent is one which will dissolve A, B and D and in which C is substantially insoluble. The reaction is readily carried out at room temperature lower temperatures, e.g. as low as 100C, may be used elevated temperatures may also be used but are not required. This process is more fully described in our copending application U.S. Serial Number 459,923, filed onJanuary 21, 1983, which is hereby incorporated by reference. Another useful process to prepare certain of the compounds of the present invention is the oxidation of certain phenothiazines or benzo a phenothiazines by standard oxidizing agents such as potassium dichromate, NaClO2, 2,3 dichloro 5,6dicyano 1,4 benzoquinone DDQ , and the like. Several of these benzota phenothiazines and phenothiazines are described in our copending applications U.S. SerialNumbers 539,342 and 539,215, respectively, both filed on October 5, 1983, which are hereby incorporated by reference. Examples for the preparation and use ofFormulae I and II compounds follow. These examples are provided merely as an aid to understand the instant invention and not as a limitation. All temperatures are in degrees Celsius and are uncorrected. EXAMPLE 1Method A 3H Phenothiazin 3 one To a stirring suspension of 1.72 kg 16 mol of P benzoquinone in 13 liters MeOH at room temperature was added slowly a solution of 1.0 kg 8 mol of 2 aminothiophenol in 600 ml MeOH over a period of 1 hour. The resulting red mixture was stirred at zoom temperature for another 2 hours and then the duct 3H phenothiaz 3 one was filtered off. This 3H phenothiazin 3 one was washed thoroughly with methanol and dried to give 1 07 kg of 3H phenothiazin 3 one 61.49 yield , m.p. 157 1590C. Method B To a stirring solution of 1.1 kg of ceric ammonium nitrate in 12.5 liters of H2O and 1.25 liters of HOAc at 100C was added dropwise a solution of 100 g of phenothiazine in 500 ml acetone over a period of 20 minutes. The resulting mixture was stirred for another 20 minutes and the product 3H phenothiazin 3 one was then filtered off. The filtered 3H phenothiazin 3 one was washed with water thoroughly and dried to give 92 g of crude 3H phenothiazin 3 one. The crude 3H phenothiazin 3 one was extracted with minimum volume of CH2Cl2. Upon dilution of the CH2C12 solution with 10 times the volume of cyclohexane, a precipitate was formed which was filtered and dried to afford 35 g of 3H phenothiazin 3 one. EXAMPLE 2 4 Chloro 3H phenothiazin 3 one To a stirring solution of 500 g 2.34 mol of 3H phenothiazin 3 one in 12.5 liters of glacial acetic acid was added 1.25 kg of potassium.dichromate. The mixture was stirred at room temperature for 1 2 hour.To this resulting mixture was then added 2.34 mol of a 1M solution of chlorine in glacial acetic acid dropwise over a period of 4 hours. The progress of the reaction was monitored by tlc to ensure no excess chlorine was added. After addition of chlorine was completed the mixture was stirred at room temperature for another 1 2 hour and was then poured into i20 liters of H20 with vigorous stirring. The 4 chloro 3H phenothiazin 3 one precipitated was allowed to settle overnight. The majority of the aqueous solution was siphoned and discarded and the rest was filtered.The filtered precipitate washed thoroughly with water and then rinsed with methanol and was allowed to dry to qive 504 g crude 4 chloro 3H phenothiaz in 3 one which as recrystallized from toluene, m.p. 2210. EXAMPLE 3 4 Chloro 2,7 dimethoxy 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 2,7 dimethoxy 3H phenothiazin 3 one for 3H phenothiazin 3 one, the title compound was obtained, m.p. 264 C.Analysis, calculated C, 54.63 H, 3.27 N, 4.55 s, 10.42 C1, 11.52.Observed C, 54.64 H, 3.31 N, 4.53 S, 10.60 Cl, 11.69. EXAMPLE 4 4 Chloro 1,7 dimethoxy 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 1,7 dimethyl 3H phenothiazin 3 one for 3H phenothiazin for 3H phenothiazin 3 one the title compound was obtained, m.p. 215 218 C.Analysis, calculated C, 60.98, H, 3.66 N, 5.08 S, 11.63 C1, 12.86.Observed C, 60.78 H, 3.75 N, 4.99 S, 11.79 Cl, 13.01. EXAMPLE 5 4 Chloro 2,7 dimethyl 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 2,7 dimethyl 3H phenothiazin 3 one for 3H phenothiazin 3 one the title compound was obtained, m.p. 193 1950C. Analysis, calculated C, 60.98 H, 3.66 N, 5.08 S, 11.63 C1, 12.86.Observed C, 60.89 H, 3.79 N, 5.22 S, 11.63 C1, 12.50. EXAMPLE 6 4 Chloro 2 methyl 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 2 methyl 3H phenothiazin 3 one for 3H phenothiazin 3 one, the title compound was obtained, m.p. 2060C.Analysis, calculated C, 59.66 H, 3.08 N, 5.35 S, 12.25 C1, 13.55.Observed C, 59.59 H, 3.35 N, 5.32 S, 12.64 C1, 13.27. EXAMPLE 7 4 Chloro 7 methyl 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 7 methyl 3H phenothiazin 3 one for phenothiazin 3 one, the title compound was obtained, m.p. 218 C. Analysis, calculated C, 59.66 H, 3.08 N, 5.35 S, 12.25 C1, 13.55.Observed C, 59.48 H, 3.17 N, 5.27 S, 12.40 C1, 13.63. EXAMPLE 8 4 Chloro 7 ethoxy 2 methoxy 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 7 ethoxy 2 methoxy 3H phenothiazin 3 one for 3H phenothiazin 3 one, the title compound was obtained, m.p. 236 239 C.Analysis calculated C, 55.99 H, 3.76 N, 4.35 S, 9.96 C1, 11.02.Observed C, 56.05, H, 3.93 N, 4.37 S, 10.11 C1, 10.99. EXAMPLE 9 4 Bromo 2 methyl 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 2 methyl 3H phenothiazin 3 one for 3H phenothiazin 3 one and substituting bromine for chlorine, the title compound was obtained, m.p. 1900C.Analysis, calculated C, 50.99 H, 2.63 N, 4.57 S, 10.47 Br, 26.09. Observed C, 50.97 H, 2.69 N, 4.61 S, 10.56 Br, 26.24. EXAMPLE 10 9 Methoxy 3H phenothiazin 3 one To a suspension of p benzoquinone 3.0 g in 15 ml methanol was added 2 amino 3 methoxythiophenol 2.2 g dissolved in 10 ml methanol. The mixture was stirred at room temperature for 45 minutes and concentrated in vacuo. The residue was triturated with ether and filtered. The resulting dark solid was chromatographed on silica gel and eluted withEtOAc, to afford the desired compound, m.p. 206 2070, Analysis, calculated C, 64.18 H, 3.73 N, 5.76 S, 13.18.Observed C, 64.10 H, 3.83 N, 5.69 S, 13.400 EXAMPLE 11 7 Fluoro 3H phenothiazin 3 one Following the procedure described in Example 10 but substituting 2 amino 5 fluorothiophenol for 2 amino 3 methoxythiophenol, the title compound was obtained, m.p. 2400C.Analysis, calculated C, 62.33 H, 2.61 N, 6.06 S, 13.86 F, 8.21.Observed C, 62.26 H, 2.70 N, 6.05 S, 14.04 F, 8.06. EXAMPLE 12 4 Chloro 7 fluoro 3H phenothiazin 3 one Following the procedure described in Example 2 but substituting 7 fluoro 3H p anothiazin 3 one for 3H phenothiazin 3 one, the title compound was obtained, m.p. 250 2550C. Analysis, calculated C, 54.25 H, 1.90 N, 5.27 S, 12.07 F, 7.15 C1, 13.34.Observed C, 54.10 H, 2.01 N, 5.35 S, 12.20 F, 7.20 C1, 13.50. EXAMPLE 13 7 Fluoro 2 methoxy 3Hphenothiazin 3 one Following the procedure described in Example 10 but substituting 2 amino 5 fluorothiophenol for 2 amino 3 methoxythiophenol and substituting 2 methoxy p benzoquinone for p benzoquinone, the title compound was obtained, m.p. 2520C.Analysis, calculated C, 59.76 H, 3.08 N, 5.36 S, 12.27 F, 7.26.Observed C, 59.60 H, 3.11 N, 5.20 S, 12.17 F, 7.33. EXAMPLE 14 2, 4 Dimethoxy 3H phenothiazin 3 one Following the procedure described in Example 10 but substituting 2 aminothiophenol for 2 amino 3methoxythiophenol and substituting 2,6 dimethoxy pbenzoquinone for p benzoquinone, the title compound was obtained, m.p. 1930C. Analysis, calculated C, 61.52 H, 4.06 N, 5.12 S, 11.73.Observed C, 61.37 H, 4.14 N, 5.16 S, 12.90. EXAMPLE 15 1,2 DimethoxY 4 methyl 3H phenothiazin 3 one Following the procedure described in Example 10 but substituting 2 aminothiophenol for 2 amino 3methoxythiophenol and substituting 2,3 dimethoxy 5methyl p benzoquinone for p benzoquinone, the title compound was obtained, m.p. 1380C.Analysis, calculated C, 6 2.70 H, 4.56 N, 4.87 S, 11.16.Observed C, 62.72 H, 4.74 N, 4.92 S, 11.28. EXAMPLE 16 1,7 Dimethyl 3H phenothiazin 3 one and 2,7 dimethyl3H phenothiazin 3 one Following the procedure described in Example 10 but substituting 2 amino 5 methylthiophenol for 2 amino 3 methoxythiophenol and substituting 2 methylp benzoquinone for p benzoquinone, a mixture of the title compounds were obtained. Chromatography on silica gel eluting with 10 EtOAc in CH2C12 afforded firstly 2,7 dimethyl 3H phenothiazin 3 one, m.p. 1770C.Analysis, calculated C, 69.70 H, 4.60 N, 5.81 S, 13.29.Observed C, 69.51 H, 4.82 N, 5.78 S, 12,27, and secondly, l,7 dimethyl 3H phenothiazin 3 one. m.p.168 1700C.Analysis calculated C, 69.70 H, 4.6U N, 5.81 S, 13.29.Observed C, 69.59 H, 4.63 N, 5.80 S, 13.40. EXAMPLE 17 2,4 Dichloro 7 fluoro 3H phenothiazin 3 one Following the procedure described in Example 10 but substituting 2 amino 5 fluorothiophenol for 2 amino 3 methoxythiophenol and substituting dichloro p benzoquinone for p benzoquinone, the title compound was obtained, m.p. 256 2580C. Analysis, calculated C, 48.02 H, 1.34 N, 4.68 S, 10.68 F, 6.33 C1, 23.62.Observed C, 47.93 H, 1.42 N, 4.63 S, 10.75 F, 6.42 C1, 23.80. EXAMPLE 18 ichloro 7 fluoro 3H phenothiazin 3 one Following the procedure described in Example 10 but substituting 2 amino 5 fluorothiophenol for 2 amino 3 methoxythiophenol and substituting 2,5 dichloro p benzoquinone for p benzoquinone, the title compound was obtained, m.p. 245 247 C. Analysis, calculated C, 48.02 H, 1.34 N, 6.33.observed C, 48.20 H, 1.14 N, 6.20. EXAMPLE 19 2 Methoxy 7 methylthio 3H phenothiazin 3 one Following the procedure described in Example 10 but substituting 2 amino 5 methylthio thiophenol for 2 amino 3 methoxythiophenol and subst tuting 2 methoxy p benzoquinone for p benzoquinr e, the title compound was obtained, m.p. 22 224 C.Analysis, calculated C, 58.11 H, 3.83 N, 4.84 S, 22.16.Observed C, 58.28 H, 4.24 N, 4.62 S, 22.02. EXAMPLE 20 4 Trifluoromethyl 3H phenothiazin 3 one and 2,4 bis trifluoromethyl 3H phenothiazin 3 one A solution of 3H phenothiazin 3 one 10 g , trifluoromethyl iodize 50 g and pyridine 40 ml in acetonitrile 140 ml was irradiated with a 450 watt lamp for 3 days. The volatiles were removed under vacuum and the resulting residue chromatographed on a silica gel golumn eluting with 5 EtOAc CH2C12 to afford firstly, 2,4 bis trifluromethyl 3H phenothiazin 3 one 650 mg m.p. 173 1750C.Analysis, calculated C, 48.14 H, 1.44 N, 4.01 S, 9.18 F, 32.64.Observed C, 48.25 H, 1.72 N, 4.00 S, 9.28 F, 32.51.Secondly, 4 trifluoromethyl 3H phenothiazin 3 one 1.76 g , m.p. 184 185 C. Analysis, calculated C, 55.51 H, 2.15 N, 4.98 S, 11.40 F, 20.27.Observed C, 55.60 H, 2.14 N, 5.22 S, 11.43 F, 20.41. EXAMPLE 21 4 Acetyl 3H phenothiazin 3 one A solution of 3H phenothiazin 3 one 2 g and acetaldehyde 32 ml in benzene 240 ml was irradiated with a 450 watt lamp for 2 days. The volatiles were removed under vacuum and the residue chromatographed on a silica gel column eluting with 25 EtOAc hexane to afford the desired compound, m.p.2220C. Analysis, calculated C, 65.87 H, 3.55 N, 5.49 S, 12.56 Observed C, 65.88 X, 3.61 N, 5.30 S, 12.70. EXAMPLE 22 4 Bromo 2,7 dimethoxy 3H phenothiazin 3 one Step 1 2 Methoxy p benzoquinone Vanillin 2.432 kg was added to a solution of sodium hydroxide 640 g in water 8 1 and cooled to 100C with an ice bath. Then a soluton of hydrogen peroxide 30 2.4 1 was added at a rate to keep the temperature of the reaction mixture below 300C. The addition completed about 2 hours , the reaction mixture was added over a period of 3 hours to a suspension of sodium periodate 880 g in water 4 1 and acetic acid 640 ml cooled with an ice bath to 100C the temperature of the reacton mixture was kept below 350C . The precipitate was filtered, washed with cold water followed by ethanol hexane 1 1 mixture and air dried to afford the title compound 1.9 kg , m.p. 144 1470C.Step 2 2 Amino 5 methoxythiophenol To a soluton of potassium hydroxide 8N 1.3 1 was added 2 amino 6 methoxybenzothiazole 750 g and the mixture was refluxed for 18 hours. The resulting solution was neutralized by the addition of concentrated HC1, to pH 8.0, then acetic acid to pH 6.0. The precipitate which formed was filtered and washed with water to afford the title compound which was used immediately in Step 3. Step 3 2,7 Dimethoxy 3H phenothiazin 3 one To a suspension of 2 methoxy p benzoquinone, 1.15 kg Step 1 in methanol 8 1 was added portionwise a suspension of 2 amino 5 methoxythiophenol from Step 2 in methanol 6 1 . The reaction mixture was stirred for 15 minutes at room temperature, filtered and the collected solid washed with methanol 8 1 . The product isolated was swished with DMF 16 1 for 2 hours, filtered and air dried. The crude material was dissolved in hotDMF 16 1 1300 1400C , filtered through Celite and the filtrate cooled to room temperature. The crystals were filtered, washed with methanol 8 1 and air dried to afford the title compound 703 g , m.p. 237 238 C. Step 4 4 Bromo 2,7 dimethoxy 3H Phenothiazin 3 one A solution of bromine 280 g in acetic acid 2.8 1 was added over a period of 30 minutes to a suspension of 2,7 dimethoxy 3H phenothiazin 3 one 250 g Step 3 in acetic acid 7.5 1 and stirred for 2 hours. Methanol 12 1 was added and the mixture was stirred until the black suspension became an orange suspension. Then, the precipitate was filtered, washed with methanol and air dried to afford the desired compound 312 g , m.p. 260 2610C.Analysis, calculated C, 47.74 H, 2.86 N, 3.98 S, 9.10 Br, 22.69.Observed C, 47.74 H, 2.81 N, 3.90 S, 9.02 Br, 22.37. EXAMPLE 23 4 Chloro 2 ethoxy 3H phenothiazin 3 one and 4 chloro2,7 diethoxy 3H phenothiazin 3 one Metallic sodium 506 mg was dissolved in absorbed ethanol 75 ml and 4 chloro 3H phenothiazin3 one 4.95 g was added and stirred overnight at room temperature. The solvent was removed in vacuo, the resulting residue stirred in acetone 500 ml for 1 hour and filtered. The filtrate was evaporated to dryness and the residue was chromatographed on a silica gel column eluting with 5 EtOAc toluene to afford firstly, 4 chloro 2 ethoxy 3H phenothiazin 3 one 1.33 g , m.p. 188 1890C. Analysis, calculated C, 57.63 H, 3.45 N, 4.80 S, 10.99 C1, 12.15.Observed C, 57.66 H, 3.5 N, 4.81 S, 11.16 C1, 12.02.and secondly, 4 chloro 2,7 diethoxy 3H phenothiazin3 one 110 mg , m.p. 227 2280C.Analysis, calculated C, 57.22 H, 4.20 N, 4.17 S, 9.55 C1, 10.56.Observed C, 57.19 H, 4.35 N, 4.07 S, 9.62 C1, 10.61. EXAMPLE 24 2 n Butylthio 3H phenothiazin 3 one To a solution of 3H phenothiazin 3 one 0.64 g in 75 ml methanol was added thiethylamine 1.0 ml and n butanethiol 0.58 ml . The mixture was stirred at room temperature for 48 hours. Then 2,3 dichloro5,6 dicyano 1,4 benzoquinone 0.67 g was added. The mixture was stirred at room temperature for 2 hours.The solvent was removed in vacuo. The residue was chromatographed on neutral alumina Act III and eluted with 15 EtOAc hexane to afford the title compound 0.4 g , m.p. 133 C. Analysis, calculated C, 63.78 H, 5.02 N, 4.65Observed C, 63.61 H, 5.04 N, 4.51. EXAMPLE 25 4 n Butylthio 3H phenothiazin 3 one To a solution of phenothiazin 3 one 0.21 g in 20 ml THF was added triethylamine 0.28 ml and n butanethiol 0.2 ml . The mixture was refluxed for 15 hours and then cooled to room temperature. 2,3 Dichloro 5,6 dicyano l,4 benzoquinone DDQ 0.22 g was added and the reaction was stirred for 2 hours at 250. The solvent was removed in vacuo. The residue was chromatographed on neutral alumina ActIII and eluted with 15 EtOAc hexane to afford the title compound, m.p. 720C.Analysis, calculated C, 63.78 H, 5.02 N, 4.05 S, 21.24.Observed C, 63.83 H, 5.07t N, 4.86 S, 21.06. EXAMPLE 26 4 n Butylthio 2 methyl 3H phenothiazin 3 one To a solution of 2 methyl phenothiazin 3 one 0.23 g in 12 ml dichloroethane was added trie hylamine 0.8 ml and n butanethiol 0.7 ml .The mixture was stirred at room temperature for 72 hours. 2,3 Dichloro 5,6 dicyano 1,4 benzoquinone 0.22 g was added. The mixture was stirred at room temperature for 2 hours. The mixture was stirred at room temperature for 2 hours. The solvent was removed in vacuo and the residue was chromatographed on neutral alumina Act III eluting with 15 EtOAc hexane to give the title compound 120 mg , m.p. 970C.Analysis, calculated C, 64.75 H, 5.43 N, 4.44.Observed C, 64.62 H, 5.53 N, 4.43. EXAMPLE 27 2 S Glutathionyl 3H phenothiazin 3 one A mixture of phenothiazin 3 one 0.22 g , triethylamine 0.41 ml and glutathione 0.3 g in 1,2 dichloroethane 12 ml was stirred at room temperature for 5 days. The solvent was removed in vacuo. The residue was dissolved in water and filtered. The filtrate was concentrated in vacuo and then chromatographed on XAD resin and eluted with water to give the title compound. EXAMPLE 28 4 Chloro 2 S glutathionylphenothizin 3 one Following the procedure of Example 27, but substituting 4 chloro 3H phenothiazine 3 one for 3H phenothiazin 3 one, the title compound was obtained. EXAMPLE 29 5H BenzoTa phenothiazin 5 one Following the procedure described in Example 10 but substituting 2 aminothiophenyl for 2 amino 3 methoxythiophenyl and substituting 1,4 naphthoquinone for p benzoquinone the title compound was obtained, m.p. 176 1770C. EXAMPLE 30 6 Chloro 5H benzo a phenothiazin 5 one Following the procedure described in Example 2, but substituting 5H benzo a phenothiazin 5 one for 3H phenothiazin 3 one, the title compound was obtained, m.p. 230 2310C. EXAMPLE 31 6 MethYl 5H benzolaXphenothiazin 5 one Following the procedure described in Example 10, but substituting 2 aminothiophenol for 2 amino 3methoxythiophenol and substituting 2 methyl 1,4naphthoquinone for p benzoquinone, the title compound was obtained, m.p. 1810C.Analysis, calculated C, 73.62 H, 4.00 N, 5.05 S, 11.56.Observed C, 73.77 H, 4.16 N, 4.99 S, 11.69. EXAMPLE 32 l Hvdroxy 6 methyl 5H phenothiazin 5 one Following the procedure described in Example 10 but substituting 2 aminothiophenol for 2 amino 3methoxythiophenol and substituting 5 hydroxy 2 methyl1,4 naphthoquinone for p benzoquinone, the title compound was obtained, m.p. 226 2280C.Analysis, calculated C, 69.61 H, 3.78 N, 4.77 S, 10.93.Observed C, 69.66 H, 3.90 N, 4.66 S, 10.77. EXAMPLE 33 l Methoxy 6 methyl 5H phenothiazin 5 one Potassium tert. butoxide 500 mg was added to a suspension of l hydroxy 6 methyl 5H benzota phenothiazin 5 one ftom Example 32 500 mg and methyl iodide 2 ml in DMF 20 ml . After 30 minutes at room temperature, EtOAc 250 ml was added followed by water 200 ml . The aqueous layer was decanted and the organic layer was dried and evaporated to dryness. The residue was treated with ether, filtered and air dried to afford the desired product 420 mg , m.p. 170 171 C.Analysis, calculated C, 70.34 H, 4.26 N, 4.56 S, 10.43.Observed C, 70.37 H, 4.44 N, 4.45 S, 10.52. EXAMPLE 34 4 Hydroxy 3H phenothiazin 3 one 5,5 dioxide To a suspension of 3 hydroxy 10H pheno thiazine 5,5 dioxide 1.75 g, 7 mmoles in 2 aqueous sulfuric acid 25 ml there was added, at room temperature, a solution of 80 sodium chlorite 3.17 g, 28 mmoles in water 25 mlZ1 The mixture was stirred for 15 minutes, then th red organge precipitate was filtered to afford crude product 1.73 g . Purification was achieved by crystallization from DMF methanol, m.p. 2660 dec. . Analysis, calculated C, 55.16 H, 2.70 N, 5,36 S, 12.27.Observed CR 4.68 H, 2.76 N, 5.38 S, 12.47. EXAMPLE 35 4 Chloro 3H phenoxazin 3 one To a solution of 1.2 g of 3H phenoxazin3 one in acetic acid 25 ml was added K2Cr2O7 3.7 g . A solution of chlorine in acetic acid was added dropwise to the resulting suspension. After disappearance of the starting material, as monitored by TLC, the reaction mixture was poured into 200 ml of H20 and the resulting precipitate was filtered 1.2 g and chromatographed on silica gel to yield the title compound.Analysis, calculated C, 62.22 H, 2.61 C1, 15.30.Observed C, 62.10 H, 2.75 C1, 15.24. EXAMPLE 36 2,4 Di t butyl 1H phenothiazin l one To a solution of 4.4 gm of 3,5 di t butyl l,2 benzoquinone in 20 ml of ether was added a solution of 1.25 g of 2 aminothiophenol in 5 ml of ether. After stirring for 1 hour at 250, the reaction mixture was evaporated. The residue was purified by flash chromatography on silica gel using 2 ethyl acetate in benzene as eluent. There was thus obtained 860 mg of the title compound as dark blue plates, m.p. 137 141 . Analysis, calculated C, 73.81 H, 7.12 N, 4.30 S, 9.85Observed C, 73.77 H, 7.33 N, 4.33 S, 9.85. EXAMPLE 37 4 Bromo 1,7 dimethoxy 3 H phenothiazin 3 one To a suspension of l,7 dimethoxy 3H phenothiazin 3 one 300 mg in acetic acid 9 ml was added a 0.63 M solution of Br2 in acetic ac5 1.92 ml . After 15 minutes, methanol was added and the solid filtered, washed with ether and air dried to afford the title compound 353 mg , m.p. 267 2700C dec . EXAMPLE 38 4 Chloro 1,7 dimethoxy 3H phenothiazin 3 one and 2,4 dichloro 1, 7 dimethoxy 2 H phenothiazin 3 one To a suspension of 1,7 dimethoxy 3H phenothiazin 3 one 800 mg in acetic acid 24 ml was added a 1.15 M solution of C12 in acetic acid 3.1 ml . After 15 minutes, methanol was added and the mixture was filtered, washed with ether and air dried to afford a mixture of the two title compounds 700 mg , which were separated on a silica gel column EtOAc CH2c12, 1 9 , affording 4 chloro 1,7dimethoxy 2H phenothiazin 3 one, m.p. 278 2800C dec. Analysis, Calculated C, 54.64 H, 3.28 N, 4.55 S, 10.42 C1, 11.52. Observed C, 54.44 H, 3.26 N, 4.62 S, 10.54 C1, 11.48.and 2,4 dichloro 1,7 dimethoxy 3H phenothiazin 3 one, m.p. 259 2600C dec. m e 341. EXAMPLE, 39 7 Methoxy 2 4 methylpiperazin l yl 3H phenothiazine 3 one A mixture of 7 methoxy 3H phenothiazin 3 one 1.2 g and N methyl piperazine HC1 3.4g in DMF 20 ml was heated at 1000C for 3 hours. Then Nail4 lg was added and the reaction mixture was heated at 100 CC for 1 hour. Ice water was added to the reaction mixture followed by ethyl acetate. The aqueous layer was decanted, filtered and the filtrate basified with K2CO3 and extracted with ethyl acetate. The organic layer was evaporated to dryness, the resulting residue was dissolved inCH2C12, dried and evaporated to dryness to afford the crude final product 1.2 g which was purified by chromatography on silica gel column eluting with 10 MEOH CH2C12 to give the title compound, m.p. 208 209 . EXAMPLE 40 4 Bromo 7 methoxy 2 4 methylpiperazin 1 yl 3H phenothiazin 3 one To a suspension of 7 methoxy 2 4 methyl piperazin l yl 3H phenothiazin 3 one 500 mg in acetic acid 10 ml was added a solution of bromine in acetic acid 0.5 M 6ml and stirred for 5 minutes. Hexane 100 ml was added and the resulting precipitate was filtered. The solid was suspended in a mixture of aqueous KC03 50 ml , EtOAc 100 ml and methanol 20 m s and stirred for 15 minutes.After filtration and decantation, the organic layer was washed with brine, dried and evaporated to dryness to afford the title compound 190 mg m.p. 209 210 dec. . EXAMPLE 41 4 Bromo 2, 7 dimethoxy 3H phenothiazin 3 one 5, 5 dioxideSTEP 1 4 Bromo 3 hydroxy 2,7 dimethoxy 10 E phenothiazine To a suspension of 4 bromo 2,7 dimethoxy3H phenothiazin 3 one 100 g in a mixture of ethylacetate 2 1 and water 1 1 was added sodium hydrosulfite 200 g in one batch with mechanical stirring. The orange reaction mixture was stirred for 15 hours under a nitrogen atmosphere. The resulting white reaction mixture was filtered and the precipitate washed with water under a nitrogen atmosphere to prevent air oxidation of the compound.The title compound 130 g was obtained as a wet material and was used as such in the next step Step 2 . An analytical sample was air dried, m.p. 1850C.Analysis, Calculated C, 47.47 H, 3.42 N, 3.95 S, 9.05 Br, 22.56.Observed C, 47.21 H, 3.39 N, 3. 4 S, 8.76 Br, 22.44.STEP 2 3 Acetoxy 4 bromo 2, 7 dimethoxy 10 H phenothiazine Wet 4 bromo 3 hydroxy 2,7 dimethoxy 10 H phenothiazine 130 g from step 1 was suspended in pyridine 230 ml . The mixture was cooled to 0 C in an ice water bath. Acetic anhydride 195 ml was then slowly added. The solution was left stirring at room temperature for 1 2 hour. The mixture was then concentrated under reduced pressure to approximately 1 3 of the original volume. The a mixture of ether hexane, 1 1 700 ml was added, causing a large amount of crystals to appear. These crystals were filtered, washed with ether, and air dried, giving 51.4 g of pure 3 acetoxy 4 bromo2,7 dimethoxy 10 phenothiazine.The mother liquors were reevaporated, and ether and hexane were added again, giving 36.37 of crude 3 acetoxy 4 bromo 2,7 dimethoxy lOH phenothiazine m.p. 201 2030C.Analysis, Calculated C, 48.50 H, 3.56 N, 3.53 S, 8.09.Observed C, 48.31 H, 3.47 N, 3.47 S, 8.00.STEP 3 3 Acetoxy 4 bromo 2,7 dimethoxy lOH phenothiazin 5, 5 dioxide To 3 acetoxy 4 bromo 2,7 dimethoxy lOHphenothiazin 20 g from Step 2 in suspension in CH2Cl2 MeOH, 1 1 500 ml , was added m chloroperoxybenzoic acid 26.0 g . The reaction mixture rapidly became deep brown with the formation of a yellowish precipitate which corresponded to the intermediate sulfoxide on the 5 position. The mixture was heated at reflux for 18 hours. The solid was then filtered and washed with ether. Since there was still some sulfoxide remaining, the solid was suspended in ethanol l,2 dichloroethane 500 ml with 1.35 g of m chloroperoxybenzoic acid and heated at reflux overnight 15 hours .The solid was then filtered and washed with ether and air dried giving 13.0 g of 3 acetoxy 4 bromo 2,7 dimethoxy lOH phenothiazine 5,5 dioxide, m.p. 2600C.Analysis, Calculated C, 44.87 H, 3.29 N, 3.27 S, 7.49Observed C, 44.82 H, 3.21 N, 3.18 S, 7.67. STEP 4 4 Bromo 3 hydroxy 4,7 dimethoxy 10H phenothiazin St5 dA x4e To a suspension of 3 acetoxy 4 bromo 2,7 dimethoxy 10H phenothiazine 5,5 dioxide 10.0 g in methanol 105 ml was added a solution cf 2N aqueous sodium hydroxide 74 mL under t nitrogen atmosphere. After 20 minutes, the mixture was acidified with 10 v v aqueous acetic acid 250 ml , causing a large amount of compound to precipitate.The mixture was then diluted with water 105 ml and the solid filtered, washed with water and ether and dried in a dessicator to afford quantitatively the title compound, m.p. 252 2600C dec .STEP 5 4 Bromo 2,7 dimethoxy 3H phenothiazin 3 one 5,5 dioxide To a stirred suspension of 4 bromo 3hydroxy 2,7 dimethoxy 10H phenothiazin 5,5dioxide from Step 4 1 g in THF 10 ml was added 2,3 dichloro 5,6 dicyano 1,4 benzoquinone 1.17 g .After 15 minutes, the mixture was filtered, the solid washed with ether and air dried. The solid was filtered through a silica gel pad withCH2C12 EtOAc, 1 1, to afford the title compound 300 mg , m.p. 228 2300C dec , m e 383. EXAMPLE 42 2,7 Dimethoxy 4 4 methylpiperazin 1 yl 3H phenothazin 3 one 5,5 dioxt 2 To a stirred suspensio of 4 bromo 3 hydroxy2,7 dimethoxy 10H phenothiazine 5,5 dioxide 1g inTHF 10 ml was added 2,3 dichloro 5,6 dicyano1,4 benzoquinone 1.17g . After a period of 20 minutes, N methyl piperazine 1.44 ml was slowly added. After 20 minutes, hexane was added to the mixture and the resulting precipitate was filtered, washed with ether and air dried.The compound was chromatographed usingCH2Cl2 MeOH 9.5 0.5 as eluant, to afford the title compound 242 mg , m.p. 2610C dec. Analysis Calculated C,SS.67 H.5.83 N, 10.80s S, 8.24 Observed C, 58.73t H,5.67 N, 10.83s S,8.56 EXAMPLE 43 44 Hydroxy 2,7 dimethoxy 3H phenothiazin 3 one 5,5 dioxide To a stirred suspension of 4 bromo 3 hydroxy 2,7 dimethoxy lOH phenothiazine 5,5 dioxide 100 mg in THF 10 ml was added water 0.1 ml and 2,3 dichloro 5,6 dicyano 1,4 benzoquinone 0.12 g . After 20 minutes, hexane was added and the solid was filtered, washed with ether and air dried to afford the title compound, m.p. 333 3350C dec. EXAMPLE 44 1,4 Bis l propylamino 3H phenothiazin 3 one 5, 5 dioxide To a solution of 3 hydroxy lOH phenothiazine 5,5 dioxide 989 mg in THF 50 ml was added 2,3 dichloro 5,6 dicyano 1,4 benzoquinone 1.82 g . The resulting green mixture was stirred at room temperature for 3 minutes, then there was added n propyl amine 2.36 g . The mixture was stirred for 20 minutes and then filtered. The filtrate was evaporated to dryness and the residue chromatographed on a column of silica gel eluting with a 1 20 mixture of ethyl acetate and dichloromethane to afford the title compound as a purple solid 850 mg . Crystallization from methane afforded purple crystals 606mg , m.p. 174 1766C Analysis, Calc d C, 60.14 H, 5.89 N, 11.69 S, 8.92. Found C, 60.08, H, 5.93 N, 11.80 S, 8.71. EXAMPLE 45 1,4 Bis 4 methylpiperazin 1 yl 3H phenothiazine 3 one S, 5 dioxide The procedure of Example 44 was used, substituting N methyl piperazine for n propyl amine to afford the title compound. It was crystallized from a toluene hexane mixture to afford red crystals, mp 247 2490C dec .Analysis, Calc d C, 59.84 H, 6.16 N, 15.86 S, 7.26Found C, 59.98, H, 6.35 N, 15.58 S, 7.1. EXAMPLE 46 6 1 Propylamino 5H benzo a3phenothiazin 5 one 7f7 dioxideSTEP 1 5 acetoxy 12H benzo a phenothiazine To a stirred solution of 5 hydroxy 12Hbenzo a phenothiazine 50 g in pyridine 115 ml was added acetic anhydride 48ml . The reaction was exothemic stirring was continued without cooling for 30 minutes, then the mixture was cooled to 100C using an ice bath. The yellow crystalline solid was filtered and washed with ether to afford the title compound 23.4 g . The product was crystallized from etyl acetate, m.p. 185 186 C. STEP 2 5 acetoxy 12H benzo a phenothiazine 7,7 dioxide To a suspension f 5 acetoxy 12H benzota phenothiazine 10 g in aichloromethane 125 ml , was added a solution of m chloroperoxybenzoic acid 18 g in methanol 125 ml . The mixture was refluxed for 2.5 hours, then after cooling to room temperature the insoluble solid was filtered to afford the desired sulfone 8.6 g . The solid was recrystallized fromTHF m.p. 284 2870C Analysis, Calc d C, 63.70 H, 3.86 N, 4.13 S, 9.45.Found C, 63.67t H, 3.82 N, 4.20 S, 9.44STEP 3 5 hydroxy 12H benzo a phenothiazine 7,7 dioxide To a suspension of 5 acetoxy 12H benzo a phenothiazine 7,7 dioxlde 6.6 g in methanol 200 ml , kept under a nitrogen atmosphere was added 2N aqueous sodium hydroxide solution 132 ml . The mixture was stirred at room temperature for 7 minutes, then there was added 10 acetic acid 200 ml and water 300 ml . After 10 minutes of stirring the mixture was filtered to afford the title compound 5.68 g as a pink solid. The solid was recrystallized from THF, m.p. 3340C dec .Analysis, Calc d C, 63.70, H, 3.86 N, 4.13 S, 9.45.Found C, 63.67, H, 3.82 N, 4.20 S, 9.44. STEP 4 6 l Propyl amino 5H benzo lal phenothiazi 5 one 7,7 dioxide To a suspension of 5 hydroxy 12H benzo a phenothiazine 7,7 dioxide 594mg in THF 10 ml was added 2,3 dichloro 5,6 dicyano 1,4 benzooquinone 1.021 gram . The mixture was stirred at room temperature for 2 minutes, then there was added n propyl amine 0.2ml . The stirring was continued for 0.5 hour, then the mixture was evaporated to dryness. To the residue was added 50 ml dichloromethane and the mixture was stirred for IS minutes and filtered. The filtate was evaporated to dryness and the residue crystallized from a mixture of toluene and hexane to afford the title compound 442 mg as a red brown crystalline solid, m.p. 149 1510C dec. .Analysis, Calc d C, 64.75 H, 4.58 N, 7.95 S, 9.10.Found C, 64.66, H, 4.48 N, 7.95 S, 9.04. EXAMPLE 6 4 Methyl piperazin 1 yl 5H benzo a pheno thiazin 5 one 7,7 dioxide The procedure of Example 46, Step 4 was used, substituting N methyl piperazine for n propyl amine, to afford the title compound, m.p. slow dec.from 1830 C.Analysis, Calc d C, 64.10 H, 4.87 N, 10.68 S, 8.15.Found C, 63.89, H, 4.90 N, 10.56 S, 8.10. EXAMPLE 48 6 Amino 5H benzo a phenothiazin 5 one 7,7 dioxide The procedure of Example 46, Step 4 was used, substituting 28 aqueous ammonium hydroxide solution for n propyl amine, to afford the title compound, m.p. 264 266dC. Certain of the compounds herein disclosed contain one or more centers of asymmetry. The present invention is meant to include the various diastereomers of such compounds as well as their racemic and optically active resolved forms. Some of the compounds described may exist in one or more tautomeric forms. All such tautomeric forms are included within the present invention. EXAMPLE 49 TEST RESULTS Following the procedure of assay B Indomethacin Induced Ulcer Assay , 4 bromo 2,7dimethoxy 3H phenothiazin 3 one was tested for ulcer inhibition. For Table 49 1, Inhibition was calculated as Mean Ulcers Control Mean Ulcers Test X X 100 Inh. Mean Ulcers Control TABLE 49 1 INDOMETHACIN INDUCED ULCER ASSAY Dose mg kg Inhibition 0.003 38 0.01 56 0.03 69 0.1 66 0.3 70 3.0 87